Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapyThomas Georgi, Vladan Vučinić, Klaus H. Metzeler et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 25
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two CasesKristin Gerhardt, Vladan Vučinić, Madlen Jentzsch et al.|Frontiers in Oncology|2021Cited by 6
Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cellsR. Weiß, Vladan Vučinić, C. P. Fernandez et al.|Hematological Oncology|2023Cited by 0
P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLSThomas Georgi, Vladan Vučinić, Carmen Fernandez-Perez et al.|HemaSphere|2023Cited by 0